Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this regi...

Full description

Saved in:
Bibliographic Details
Main Authors: Arslan, Aysenur (Author) , Labuhn, Svenja (Author) , Sala, Elisa (Author) , Ringhoffer, Mark (Author) , Schetelig, Johannes (Author) , Schröder, Thomas (Author) , Bug, Gesine (Author) , Franke, Georg-Nikolaus (Author) , Stelljes, Matthias (Author) , Dreger, Peter (Author) , Zeiser, Robert (Author) , Teschner, Daniel (Author) , Bethge, Wolfgang (Author) , Eder, Matthias (Author) , Edinger, Matthias (Author) , Amann, Elisa Maria (Author) , Neuchel, Christine (Author) , Schmid-Möglich, Amelie (Author) , Schmeller, Sandra (Author) , Beyersmann, Jan (Author) , Schrezenmeier, Hubert (Author) , Mytilineos, Joannis (Author) , Kröger, Nicolaus (Author) , Fürst, Daniel (Author)
Format: Article (Journal)
Language:English
Published: December 10 2024
In: Blood advances
Year: 2024, Volume: 8, Issue: 23, Pages: 6104-6113
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024013719
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2024013719
Get full text
Author Notes:Aysenur Arslan, Svenja Labuhn, Elisa Sala, Mark Ringhoffer, Johannes Schetelig, Thomas Schröder, Gesine Bug, Georg-Nikolaus Franke, Matthias Stelljes, Peter Dreger, Robert Zeiser, Daniel Teschner, Wolfgang Bethge, Matthias Eder, Matthias Edinger, Elisa Maria Amann, Christine Neuchel, Amelie Schmid-Möglich, Sandra Schmeller, Jan Beyersmann, Hubert Schrezenmeier, Joannis Mytilineos, Nicolaus Kröger, and Daniel Fürst, on behalf of the German Registry for Stem Cell Transplantation

MARC

LEADER 00000caa a2200000 c 4500
001 1927856736
003 DE-627
005 20250913141612.0
007 cr uuu---uuuuu
008 250610s2024 xx |||||o 00| ||eng c
024 7 |a 10.1182/bloodadvances.2024013719  |2 doi 
035 |a (DE-627)1927856736 
035 |a (DE-599)KXP1927856736 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Arslan, Aysenur  |e VerfasserIn  |0 (DE-588)1075655811  |0 (DE-627)833614967  |0 (DE-576)444443592  |4 aut 
245 1 0 |a Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany  |c Aysenur Arslan, Svenja Labuhn, Elisa Sala, Mark Ringhoffer, Johannes Schetelig, Thomas Schröder, Gesine Bug, Georg-Nikolaus Franke, Matthias Stelljes, Peter Dreger, Robert Zeiser, Daniel Teschner, Wolfgang Bethge, Matthias Eder, Matthias Edinger, Elisa Maria Amann, Christine Neuchel, Amelie Schmid-Möglich, Sandra Schmeller, Jan Beyersmann, Hubert Schrezenmeier, Joannis Mytilineos, Nicolaus Kröger, and Daniel Fürst, on behalf of the German Registry for Stem Cell Transplantation 
246 3 3 |a Outcomes of haploidentical transplants with PT-CY vs ten/ten MUD transplants with ATG in Germany 
264 1 |c December 10 2024 
300 |b Illustrationen 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht: 3. Dezember 2024 
500 |a Gesehen am 10.06.2025 
520 |a Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this registry-based retrospective study, we compared the outcomes of allo-HSCTs from 10/10 MUDs with antithymocyte globulin (ATG)-based regimens (n = 7050) vs haploidentical transplants (Haplo-Tx) using posttransplant cyclophosphamide (PT-CY Haplo; n = 487) in adult patients with hematologic malignancies between 2010 and 2020. Cox proportional hazard-and competing risks regression models were formed to compare the outcomes. Overall survival (OS), Disease-free survival (DFS), and graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS) were superior for 10/10 MUDs (OS [hazard ratio (HR), 1.27; 95% confidence interval (CI), 1.10-1.47; P = .001]; DFS [HR, 1.17; CI, 1.02-1.34; P = .022]; GRFS [HR, 1.34; CI, 1.19-1.50; P < .001]). The risk of acute GVHD (aGVHD) grade 2 to 4, aGVHD grade 3 to 4, and chronic GVHD (cGVHD) was higher in the PT-CY Haplo group than the 10/10 MUD group (aGVHD grade 2-4 [HR, 1.46; CI, 1.25-1.71; P < .001]; aGVHD grade 3-4 [HR, 1.74; CI, 1.37- 2.20; P < .001]; cGVHD [HR, 1.30; CI, 1.11-1.51; P = .001]). A lower incidence of relapse was observed in the PT-CY Haplo group (relapse: HR, 0.83; CI, 0.69-0.99; P = .038). Unrelated 10/10 matched transplantation with ATG leads to lower GVHD rates and improved survival rates compared with PT-CY Haplo transplantation in Germany. 
700 1 |a Labuhn, Svenja  |e VerfasserIn  |4 aut 
700 1 |a Sala, Elisa  |e VerfasserIn  |4 aut 
700 1 |a Ringhoffer, Mark  |e VerfasserIn  |4 aut 
700 1 |a Schetelig, Johannes  |e VerfasserIn  |4 aut 
700 1 |a Schröder, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Bug, Gesine  |e VerfasserIn  |4 aut 
700 1 |a Franke, Georg-Nikolaus  |e VerfasserIn  |4 aut 
700 1 |a Stelljes, Matthias  |e VerfasserIn  |4 aut 
700 1 |a Dreger, Peter  |e VerfasserIn  |0 (DE-588)1028891881  |0 (DE-627)732699894  |0 (DE-576)376320966  |4 aut 
700 1 |a Zeiser, Robert  |e VerfasserIn  |4 aut 
700 1 |a Teschner, Daniel  |e VerfasserIn  |4 aut 
700 1 |a Bethge, Wolfgang  |e VerfasserIn  |4 aut 
700 1 |a Eder, Matthias  |e VerfasserIn  |4 aut 
700 1 |a Edinger, Matthias  |e VerfasserIn  |4 aut 
700 1 |a Amann, Elisa Maria  |e VerfasserIn  |4 aut 
700 1 |a Neuchel, Christine  |e VerfasserIn  |4 aut 
700 1 |a Schmid-Möglich, Amelie  |e VerfasserIn  |4 aut 
700 1 |a Schmeller, Sandra  |e VerfasserIn  |4 aut 
700 1 |a Beyersmann, Jan  |e VerfasserIn  |4 aut 
700 1 |a Schrezenmeier, Hubert  |e VerfasserIn  |4 aut 
700 1 |a Mytilineos, Joannis  |e VerfasserIn  |4 aut 
700 1 |a Kröger, Nicolaus  |e VerfasserIn  |4 aut 
700 1 |a Fürst, Daniel  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Blood advances  |d Washington, DC : American Society of Hematology, 2016  |g 8(2024), 23 vom: Dez., Seite 6104-6113  |h Online-Ressource  |w (DE-627)873588312  |w (DE-600)2876449-3  |w (DE-576)48043249X  |x 2473-9537  |7 nnas  |a Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany 
773 1 8 |g volume:8  |g year:2024  |g number:23  |g month:12  |g pages:6104-6113  |g extent:10  |a Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany 
856 4 0 |u https://doi.org/10.1182/bloodadvances.2024013719  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20250610 
993 |a Article 
994 |a 2024 
998 |g 1028891881  |a Dreger, Peter  |m 1028891881:Dreger, Peter  |d 910000  |d 910100  |e 910000PD1028891881  |e 910100PD1028891881  |k 0/910000/  |k 1/910000/910100/  |p 10 
999 |a KXP-PPN1927856736  |e 4732829384 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title":"Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany","title_sort":"Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"titleAlt":[{"title":"Outcomes of haploidentical transplants with PT-CY vs ten/ten MUD transplants with ATG in Germany"}],"recId":"1927856736","origin":[{"dateIssuedDisp":"December 10 2024","dateIssuedKey":"2024"}],"id":{"doi":["10.1182/bloodadvances.2024013719"],"eki":["1927856736"]},"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"note":["Online veröffentlicht: 3. Dezember 2024","Gesehen am 10.06.2025"],"relHost":[{"part":{"issue":"23","extent":"10","pages":"6104-6113","year":"2024","text":"8(2024), 23 vom: Dez., Seite 6104-6113","volume":"8"},"language":["eng"],"title":[{"title":"Blood advances","title_sort":"Blood advances"}],"pubHistory":["Vol. 1, iss. 1 (November 2016)-"],"name":{"displayForm":["American Society of Hematology"]},"note":["Gesehen am 27.04.21"],"id":{"eki":["873588312"],"zdb":["2876449-3"],"issn":["2473-9537"]},"disp":"Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in GermanyBlood advances","physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"873588312","origin":[{"publisher":"American Society of Hematology","dateIssuedDisp":"[2016]-","publisherPlace":"Washington, DC"}]}],"name":{"displayForm":["Aysenur Arslan, Svenja Labuhn, Elisa Sala, Mark Ringhoffer, Johannes Schetelig, Thomas Schröder, Gesine Bug, Georg-Nikolaus Franke, Matthias Stelljes, Peter Dreger, Robert Zeiser, Daniel Teschner, Wolfgang Bethge, Matthias Eder, Matthias Edinger, Elisa Maria Amann, Christine Neuchel, Amelie Schmid-Möglich, Sandra Schmeller, Jan Beyersmann, Hubert Schrezenmeier, Joannis Mytilineos, Nicolaus Kröger, and Daniel Fürst, on behalf of the German Registry for Stem Cell Transplantation"]},"person":[{"family":"Arslan","given":"Aysenur","role":"aut","display":"Arslan, Aysenur"},{"role":"aut","given":"Svenja","display":"Labuhn, Svenja","family":"Labuhn"},{"family":"Sala","display":"Sala, Elisa","given":"Elisa","role":"aut"},{"display":"Ringhoffer, Mark","given":"Mark","role":"aut","family":"Ringhoffer"},{"family":"Schetelig","display":"Schetelig, Johannes","given":"Johannes","role":"aut"},{"family":"Schröder","display":"Schröder, Thomas","given":"Thomas","role":"aut"},{"family":"Bug","role":"aut","given":"Gesine","display":"Bug, Gesine"},{"family":"Franke","role":"aut","given":"Georg-Nikolaus","display":"Franke, Georg-Nikolaus"},{"display":"Stelljes, Matthias","role":"aut","given":"Matthias","family":"Stelljes"},{"family":"Dreger","role":"aut","given":"Peter","display":"Dreger, Peter"},{"family":"Zeiser","display":"Zeiser, Robert","given":"Robert","role":"aut"},{"display":"Teschner, Daniel","role":"aut","given":"Daniel","family":"Teschner"},{"family":"Bethge","display":"Bethge, Wolfgang","given":"Wolfgang","role":"aut"},{"display":"Eder, Matthias","role":"aut","given":"Matthias","family":"Eder"},{"role":"aut","given":"Matthias","display":"Edinger, Matthias","family":"Edinger"},{"family":"Amann","given":"Elisa Maria","role":"aut","display":"Amann, Elisa Maria"},{"role":"aut","given":"Christine","display":"Neuchel, Christine","family":"Neuchel"},{"family":"Schmid-Möglich","given":"Amelie","role":"aut","display":"Schmid-Möglich, Amelie"},{"family":"Schmeller","role":"aut","given":"Sandra","display":"Schmeller, Sandra"},{"family":"Beyersmann","display":"Beyersmann, Jan","role":"aut","given":"Jan"},{"display":"Schrezenmeier, Hubert","role":"aut","given":"Hubert","family":"Schrezenmeier"},{"family":"Mytilineos","given":"Joannis","role":"aut","display":"Mytilineos, Joannis"},{"family":"Kröger","display":"Kröger, Nicolaus","role":"aut","given":"Nicolaus"},{"family":"Fürst","display":"Fürst, Daniel","given":"Daniel","role":"aut"}]} 
SRT |a ARSLANAYSEOUTCOMESOF1020